Leonardo Brunetti

@Brunet3Leon

Research Fellow @DanaFarber (US) | PhD Student @MaastrichtUniversity (NL) | Honorary Lecturer @ImperialCollege (UK) ThoracicOncologist #Immunotherapy enthusiast

Boston, MA Joined October 2011

340 Following 204 Followers 76 Posts

Latest posts 5

Leonardo Brunetti @Brunet3Leon Oct 26

Congrats to #ESMO26 committee for selecting such a thought-provoking trial for the plenary session, to the investigators for the bold idea and to @DrJNaidoo for the great discussion! Results could be inconclusive but there’s so much we can learn from this trial!
#ESMOAmbassadors

ESMO - Eur. Oncology Verified account @myESMO Oct 26

#ESMO26: Data from the MOIO trial were inconclusive regarding whether de-escalating #immunotherapy is beneficial after previous response to 6-month #ImmuneCheckpointInhibitor therapy in patients with a range of advanced #SolidTumours.
#InsightsbyESMO ➡️ow.ly/9WhK51002S2

View quoted post on X

Leonardo Brunetti @Brunet3Leon Oct 26

Congrats to the GFPC team on PERSEE at #ESMO26 👏
PD-L1 ≥50% NSCLC: pembro + chemo vs pembro alone • mPFS 16.1 vs 6.9 mo (HR 0.56) • ORR 78% vs 50% • OS trend (HR 0.77, NS) • G≥3 TRAEs 54% vs 19%
Randomised evidence for an everyday question in Europe.
#ESMOAmbassadors

Leonardo Brunetti @Brunet3Leon Oct 25

A new SoC enters the #KRASG12C room breaking down the door! Divarasib improves both PFS and OS vs Sotorasib/Adagrasib
#ESMO26 #ESMOAmbassadors
@FSkoulidis

Leonardo Brunetti @Brunet3Leon Oct 25

#ESMO26 multispecifics: • INCA33890 (TGFβR2×PD-1) + FOLFOX/bev, 1L MSS CRC: ORR 65% • CS2009 (PD-1×VEGF×CTLA-4) + XELOX, 1L mCRC: ORR 59% • XmAb819 (ENPP3×CD3), pretreated ccRCC: ORR ≤45%, but G≥3 TRAEs 72%

#ESMOAmbassadors

ESMO - Eur. Oncology Verified account @myESMO Oct 25

Interest is growing in multispecific antibodies to target tumour types that are unresponsive to current #immunotherapy, as illustrated by #ClinicalTrials presented at #ESMO26 in #ColorectalCancer and #ClearCellRenalCellCarcinoma

🔗 ow.ly/Q2vW50ZZsq4

#InsightsbyESMO

@MdCurioni

View quoted post on X

Leonardo Brunetti @Brunet3Leon Oct 24

Striking results from DeLLphi-305 in SCLC topped with an emotional standing ovation. Mainteinance Tarlatamab is actually more like a second induction-treatment rather than a proper mainteinance! Kudos to @sands_jacob for the magistral presentation
#ESMO26 #ESMOAmbassadors